University of California

Merial Limited

University of Pretoria

Nigel James MacLachlan

Jiansheng Yao

Jean-Christophe Francis Audonnet

Jules Maarten Minke

Jean Christophe Francis Audonnet

Kemal Karaca

Alan John Guthrie

Kermal Karaca

The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.

Vaccine against african horse sickness virus

The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against, more specifically bluetongue virus (BTV) in an animal susceptible to BTV infection. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain heterologous nucleic acid molecule(s), expresses in vivo in the animal BTV antigen, immunogen or epitope thereof, e.g., BTV VP2; BTV VP2 and VP5; BTV VP2 and VP5 and VP3 and/or VP7. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated. 

Recombinant vaccine against bluetongue virus

Growing community of inventors

Davis, CA, United States of America

Nigel James MacLachlan